69685-22-9
69685-22-9 structure
- Name: Butaprost
- Chemical Name: Butaprost
- CAS Number: 69685-22-9
- Molecular Formula: C24H40O5
- Molecular Weight: 408.571
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2017-04-15 10:26:07
- Modify Date: 2024-01-02 10:43:45
-
Butaprost is a selective prostaglandin E receptor (EP2) agonist with a Ki of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost effectively mitigates renal fibrogenesis[1][2][3].
| Name | Butaprost |
|---|---|
| Synonyms |
17,20-Cycloprost-13-en-1-oic acid, 11,16-dihydroxy-9-oxo-17-propyl-, methyl ester, (11α,13E,16S)-
Methyl (11α,13E,16S)-11,16-dihydroxy-9-oxo-17-propyl-17,20-cycloprost-13-en-1-oate |
| Description | Butaprost is a selective prostaglandin E receptor (EP2) agonist with a Ki of 2.4 μM for murine EP2 receptor. Butaprost is less activity against murine EP1, EP3 and EP4 receptors. Butaprost effectively mitigates renal fibrogenesis[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
m-EP2 receptor:2400 nM (Ki) m-EP2 receptor:33 nM (EC50) |
| In Vitro | Butaprost (1-100 nM; 0.5-24 hours) induces about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells in a dose- and time-dependent. Butaprost upregulated Nur77 gene expression through the PKC pathway[1]. Butaprost (50 μM; 24 hours) reduces TGF-β-induced fibronectin (FN) expression, Smad2 phosphorylation and epithelial-mesenchymal transition in Madin-Darby Canine Kidney (MDCK) cells[2]. Western Blot Analysis[1] Cell Line: HEK 293/EBNA cells stably expressing the human EP2 receptor (hEP2-HEK 293/EBNA cells) Concentration: 1 nM, 10 nM, 100 nM Incubation Time: 0.5 hours, 1 hours, 6 hours, 24 hours Result: Induced about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells. |
| In Vivo | Butaprost (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment attenuates the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a reduction in the gene and protein expression of α-smooth muscle actin, fibronectin and collagen 1A1[2]. Animal Model: Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery[2] Dosage: 1 mg/kg, 2 mg/kg, 4 mg/kg Administration: Intraperitoneal injection; twice daily; for 7 days Result: Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 525.1±50.0 °C at 760 mmHg |
| Molecular Formula | C24H40O5 |
| Molecular Weight | 408.571 |
| Flash Point | 168.4±23.6 °C |
| Exact Mass | 408.287567 |
| PSA | 83.83000 |
| LogP | 3.51 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.539 |